

45 980

SEARCH REQUEST FORM

U.S. DEPARTMENT OF COMMERCE
Patent and Trademark Office

Requestor's Name: Irene Marx Serial Number: 09/582 482
Date: 7/3/01 Phone: 308-29 22 Art Unit: 1651
11801
mail
box
10 E O S

Search Topic:

Please write a detailed statement of search topic. Describe specifically as possible the subject matter to be searched. Define any terms that may have a special meaning. Give examples or relevant citations, authors, keywords, etc., if known. For sequences, please attach a copy of the sequence. You may include a copy of the broadest and/or most relevant claim(s).

Please search inventors

enzymatic process 4 hydroxypruvate (HPP)

→ homogentisate (HMO)

HPP $\xrightarrow{\text{enz 1}}$ 4-hydroxyphenyl acetate (HPA)

HPA $\xrightarrow{\text{enz 2}}$ HMO

a) enz 1 = HPP-oxidase -
bacteria
Arthrobacter

b) enz 2 = HPA hydroxylase
Pseudomonas
Xanthobacter
Flavobacterium
Bacillus
Nocardia
Rhodococcus

Point of Contact:
Susan Hanley
Technical Info. Specialist
CM1 12C14 Tel: 305-4053

enz 1 + enz 2 1 pot reaction

41

STAFF USE ONLY

7/3
Date completed: 7/25
Searcher: Hanley
Terminal time: 60
Elapsed time: 40
CPU time: _____
Total time: _____
Number of Searches: _____
Number of Databases: _____

Search Site
____ STIC
____ CM-1
____ Pre-S
Type of Search
____ N.A. Sequence
____ A.A. Sequence
3 Structure
____ Bibliographic

Vendors
____ IG
9465 STN
____ Dialog
____ APS
____ Geninfo
____ SDC
____ DARC/Questel
____ Other

=> d his

(FILE 'HOME' ENTERED AT 19:09:17 ON 25 JUL 2001)

FILE 'HCAPLUS' ENTERED AT 19:09:31 ON 25 JUL 2001

L1 20 S DEROSE R?/AU
 L2 22 S SAILLAND A?/AU
 L3 40 S L1-2
 L4 264 S HOMOGENITISAT?
 L5 3 S L3 AND L4
 SELECT RN L5 1-3

FILE 'REGISTRY' ENTERED AT 19:10:48 ON 25 JUL 2001

L6 9 S E1-9
 E HOMOGENITISAT/CN
 L7 1 S E12
 E HPP/CN
 L8 1 S L6 AND C8 H8 O3/MF
 E 4-HYDROXYBENZENEACETAT/CN
 L9 1 S E5
 L10 1 S L6 AND C9 H8 O4/MF
 E 3-(P-HYDROXYPHENYL) PYRUVAT/CN

inventor search

FILE 'HCAPLUS' ENTERED AT 19:23:05 ON 25 JUL 2001

L11 3 S L5 AND L6 *3 cites w/ 9 epds displayed*
 L12 3008 S L7 OR HOMOGENITISAT? OR HMO OR HOMOGENITISIC ACID *← HMO*
 L13 6500 S HPA OR 4-HYDROXYPHENYL(W)ACET? OR L8-9 *← HPA*
 L14 105 S L12 AND L13
 L15 0 S L12(L) PREP/RL AND L13(L) RCT/RL
 L16 3 S L12(L) PREP/RL AND L13
 L17 200879 S ?HYDROXYLASE? OR ?OXYGENASE? OR PSEUDOMONAS OR XANTHOBACTER
 L18 21 S L14 AND L17
 L19 24 S L16 OR L18
 S 55326-44-8/REG# *HPA hydroxylase*

FILE 'REGISTRY' ENTERED AT 19:40:11 ON 25 JUL 2001

L20 1 S 55326-44-8/RN

FILE 'HCAPLUS' ENTERED AT 19:40:11 ON 25 JUL 2001

L21 14 S L20
 L22 7 S L21 AND L14
 L23 24 S L19 OR L22 *24 cites for HPA → HMO by enz of bug*
 L24 2068 S L10 OR HPP OR ?HYDROXYPHENYLPYRUV?
 L25 124 S L24 AND L13 *HPA*
 L26 3 S L13(L) PREP/RL AND L24
 S 78213-74-8/REG# OR ?OXIDASE? OR BACTERI## OR ARTHROBACTER

FILE 'REGISTRY' ENTERED AT 19:43:58 ON 25 JUL 2001

L27 1 S 78213-74-8/RN *HPD oxidase*

FILE 'HCAPLUS' ENTERED AT 19:43:59 ON 25 JUL 2001

L28 2 S L27
 L29 492510 S L28 OR ?OXIDASE? OR BACTERI## OR ARTHROBACTER
 L30 22 S L29 AND L25
 L31 23 S L28 OR L30 *23 cites for HPP [O] → HPA*
 L32 3 S L23 AND L31
 L33 2 S L32 NOT L11 *2 cites have both 1/2 rxn's*
 L34 23 S L30-31
 L35 20 S L34 NOT L32 *20 cites w/ either 1/2 rxn*
 L36 3 S L12(L) BPN/RL
 L37 9 S L13(L) BPN/RL
 L38 1 S L36 AND L37 *BPN/RL = biosynthetic prep/role*
 L39 0 S L38 NOT L11
 L40 2 S L36 NOT L11
 L41 2 S L40 NOT L23 *2 cites*
 L42 8 S L37 NOT (L36 OR L31) *8 cites*

FILE 'CASREACT' ENTERED AT 19:56:20 ON 25 JUL 2001

L43 STR
 L44 0 S L43

L45
L46
L47
L48
L49
L50

1 S L43 FUL ← HPA (enz) → Hmo
STR L43
0 S L46
2 S L46 FUL ← HPP [ox] → HPA
1 S L45 AND L48
1 S L48 NOT L49 ←
cite w/ both 1/2 rxn's (dypol-work)
non enzymatic

Cas 1/2 rxn
react


MARX 09/582,402

=> d que 145

L43

STR

PRO



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 23

STEREO ATTRIBUTES: NONE

L45 1 SEA FILE=CASREACT SSS FUL L43 (1 REACTIONS)


Cas react $\frac{1}{2}$ rxn

MARX 09/582,402

=> d que 148

L46

STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 24


STEREO ATTRIBUTES: NONE

L48 2 SEA FILE=CASREACT SSS FUL L46 (2 REACTIONS)


=> d bib abs hitstr 1

L11 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2001 ACS
 AN 1999:785817 HCAPLUS
 DN 131:350339
 TI Process for enzymic preparation of **homogentisate**
 IN Sailland, Alain; Derose, Richard
 PA Rhone Poulenc Agrochimie, Fr.
 SO Fr. Demande, 11 pp.
 CODEN: FRXXBL
 DT Patent
 LA French
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2772789	A1	19990625	FR 1997-16727	19971224
	FR 2772789	B1	20001124		
	WO 9934008	A1	19990708	WO 1998-FR2819	19981222
	W:		AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM		
	RW:		GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG		
	AU 9918808	A1	19990719	AU 1999-18808	19981222
	EP 1042496	A1	20001011	EP 1998-963586	19981222
	R:		AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI		
PRAI	FR 1997-16727	A	19971224		
	WO 1998-FR2819	W	19981222		
OS	CASREACT 131:350339				
AB	A procedure for producing homogentisate from 4-hydroxyphenylpyruvate is disclosed, characterized in that it consists of sequential enzymic reactions: conversion of 4-hydroxyphenylpyruvate to 4-hydroxyphenylacetate by an appropriate enzyme, followed by conversion of 4-hydroxyphenylacetate to homogentisate by a 2nd enzyme.				
IT	451-13-8P, Homogentisic acid RL: BMF (Bioindustrial manufacture); BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation) (enzymic prepn. of homogentisate)				
RN	451-13-8 HCAPLUS				
CN	Benzenecetic acid, 2,5-dihydroxy- (9CI) (CA INDEX NAME)				



IT 156-38-7P, 4-Hydroxyphenylacetic acid
 RL: BPN (Biosynthetic preparation); BPR (Biological process); BIOL (Biological study); PREP (Preparation); PROC (Process)
 (enzymic prepn. of **homogentisate**)
 RN 156-38-7 HCAPLUS
 CN Benzenecetic acid, 4-hydroxy- (9CI) (CA INDEX NAME)



IT 55326-44-8P 78213-74-8P, 4-Hydroxyphenylpyruvate oxidase
 RL: BPN (Biosynthetic preparation); CAT (Catalyst use); BIOL (Biological)

MARX 09/582,402

study); PREP (Preparation); USES (Uses)
(enzymic prepn. of homogentisate)

RN 55326-44-8 HCAPLUS

CN Oxygenase, 4-hydroxyphenylacetate 1-mono- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

RN 78213-74-8 HCAPLUS

CN Oxidase, p-hydroxyphenylpyruvate (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***


IT 156-39-8

RL: BPR (Biological process); RCT (Reactant); BIOL (Biological study);
PROC. (Process)

(enzymic prepn. of homogentisate)

RN 156-39-8 HCAPLUS

CN Benzenepropanoic acid, 4-hydroxy-.alpha.-oxo- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 2

L11 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2001 ACS
 AN 1999:554971 HCAPLUS
 DN 131:283292
 TI Crystal structure of Pseudomonas fluorescens 4-hydroxyphenylpyruvate
 dioxygenase: an enzyme involved in the tyrosine degradation pathway
 AU Serre, Laurence; Sailland, Alain; Sy, Denise; Boudec, Philippe;
 Rolland, Anne; Pebay-Peyroula, Eva; Cohen-Addad, Claudine
 CS Institut de Biologie Structurale "Jean-Pierre Ebel", CNRS/CEA, Grenoble,
 38027, Fr.
 SO Structure (London) (1999), 7(8), 977-988
 CODEN: STRUE6; ISSN: 0969-2126
 PB Current Biology Publications
 DT Journal
 LA English
 AB In plants and photosynthetic bacteria, the tyrosine degradn. pathway is
 crucial because **homogentisate**, a tyrosine degradn. product, is a
 precursor for the biosynthesis of photosynthetic pigments, such as
 quinones or tocopherols. **Homogentisate** biosynthesis includes a
 decarboxylation step, a dioxygenation and a rearrangement of the pyruvate
 sidechain. This complex reaction is carried out by a single enzyme,
 4-hydroxyphenylpyruvate dioxygenase (I), a non-heme Fe-dependent enzyme
 that is active as a homotetramer in bacteria and as a homodimer in plants.
 Moreover, in humans, I deficiency is found to be related to tyrosinemia, a
 rare hereditary disorder of tyrosine catabolism. Here, the authors report
 the crystal structure of P. fluorescens I refined to 2.4 Å. resolu.
 (Rfree = 27.6%; R-factor = 21.9%). The general topol. of the protein
 comprised 2 barrel-shaped domains and was similar to the structures of
 Pseudomonas 2,3-dihydroxybiphenyl dioxygenase (II) and P. putida catechol
 2,3-dioxygenase (III). Each structural domain contained 2 repeated
 .beta..alpha..beta..beta..alpha. modules. There was 1 non-heme Fe
 atom per monomer liganded to the side-chains of His-161, His-240, Glu-322,
 and 1 acetate mol. The anal. of the I structure and its superposition
 with the structures of II and III highlighted some important differences
 in the active sites of these enzymes. These comparisons also suggested
 that the pyruvate part of the I substrate (4-hydroxyphenylpyruvate) and
 the O2 mol. would occupy the 3 free coordination sites of the catalytic Fe
 atom. This substrate-enzyme model will aid the design of new inhibitors
 of the **homogentisate** biosynthesis reaction.
 IT 7439-89-6, Iron, biological studies
 RL: BPR (Biological process); PRP (Properties); BIOL (Biological study);
 PROC (Process)
 (coordination of iron in Pseudomonas fluorescens 4-
 hydroxyphenylpyruvate dioxygenase)
 RN 7439-89-6 HCAPLUS
 CN Iron (7CI, 8CI, 9CI) (CA INDEX NAME)

Fe

IT 9029-72-5, 4-Hydroxyphenylpyruvate dioxygenase
 RL: PEP (Physical, engineering or chemical process); PRP (Properties);
 PROC (Process)
 (crystal structure of Pseudomonas fluorescens 4-hydroxyphenylpyruvate
 dioxygenase)
 RN 9029-72-5 HCAPLUS
 CN Oxygenase, 4-hydroxyphenylpyruvate di- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***
 RE.CNT 50
 RE
 (1) Awata, H; Genomics 1994, V23, P534 HCAPLUS
 (3) Bergdoll, M; Protein Sci 1998, V7, P1661 HCAPLUS
 (4) Bradley, F; J Biol Chem 1986, V261, P11693 HCAPLUS
 (7) Cameron, A; EMBO J 1997, V16, P3386 HCAPLUS
 (8) Carson, M; Methods Enzymol 1997, V277, P493 HCAPLUS
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

MARX 09/582,402

=> d bib abs hitstr 3

L11 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2001 ACS

AN 1997:544849 HCAPLUS

DN 127:244756

TI Subcellular localization and purification of a p-hydroxyphenylpyruvate dioxygenase from cultured carrot cells and characterization of the corresponding cDNA

AU Garcia, Isabelle; Rodgers, Matthew; Lenne, Catherine; Rolland, Anne; Sailland, Alain; Matringe, Michel

CS Unite Mixte CNRS/Rhone-Poulenc (UMR 41), Rhone-Poulenc Agrochimie, Lyon, 69263, Fr.

SO Biochem. J. (1997), 325(3), 761-769

CODEN: BIJOAK; ISSN: 0264-6021

PB Portland Press

DT Journal

LA English

AB P-Hydroxyphenylpyruvate dioxygenase catalyzes the transformation of p-hydroxyphenylpyruvate into **homogentisate**. In plants this enzyme has a crucial role because **homogentisate** is the arom. precursor of all prenyl-quinones. Furthermore this enzyme was recently identified as the mol. target for new families of potent herbicides. In this study we examine precisely the localization of p-hydroxyphenylpyruvate dioxygenase activity within carrot cells. Our results provide evidence that, in cultured carrot cells, p-hydroxyphenylpyruvate dioxygenase is assocd. with the cytosol. Purifn. and SDS/PAGE anal. of this enzyme revealed that its activity is assocd. with a polypeptide of 45-46 kDa. This protein specifically cross-reacts with an antiserum raised against the p-hydroxyphenylpyruvate dioxygenase of *Pseudomonas fluorescens*. Gel-filtration chromatog. indicates that the enzyme behaves as a homodimer. We also report the isolation and nucleotide sequence of a cDNA encoding a carrot p-hydroxyphenylpyruvate dioxygenase. The nucleotide sequence (1684 bp) encodes a protein of 442 amino acid residues with a mol. mass of 48094 Da and shows specific C-terminal regions of similarity with other p-hydroxyphenylpyruvate dioxygenases. This cDNA encodes a functional p-hydroxyphenylpyruvate dioxygenase, as evidenced by expression studies with transformed *Escherichia coli* cells. Comparison of the N-terminal sequence of the 45-46 kDa polypeptide purified from carrot cells with the deduced peptide sequence of the cDNA confirms that this polypeptide supports p-hydroxyphenylpyruvate dioxygenase activity. Immunodetection studies of the native enzyme in carrot cellular exts. reveal that N-terminal proteolysis occurs during the process of purifn. This proteolysis explains the difference in mol. masses between the purified protein and the deduced polypeptide.

IT 195397-27-4P

RL: BOC (Biological occurrence); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation) (amino acid sequence; cytosolic localization and purifn. of homodimeric p-hydroxyphenylpyruvate dioxygenase from cultured carrot cells and sequencing of corresponding cDNA)

RN 195397-27-4 HCAPLUS

CN Oxygenase, 4-hydroxyphenylpyruvate di- (carrot) (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 9029-72-5P, p-Hydroxyphenylpyruvate dioxygenase

RL: BOC (Biological occurrence); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); OCCU (Occurrence); PREP (Preparation) (cytosolic localization and purifn. of homodimeric p-hydroxyphenylpyruvate dioxygenase from cultured carrot cells and sequencing of corresponding cDNA)

RN 9029-72-5 HCAPLUS

CN Oxygenase, 4-hydroxyphenylpyruvate di- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 194130-55-7, GenBank U87257

RL: BOC (Biological occurrence); PRP (Properties); BIOL (Biological study); OCCU (Occurrence) (nucleotide sequence; cytosolic localization and purifn. of homodimeric

MARX 09/582,402

p-hydroxyphenylpyruvate dioxygenase from cultured carrot cells and
sequencing of corresponding cDNA)

RN 194130-55-7 HCAPLUS

CN DNA (carrot 4-hydroxyphenylpyruvate dioxygenase cDNA plus flanks) (9CI)
(CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

=> d bib abs hitstr 1


L33 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2001 ACS
 AN 1995:733116 HCAPLUS
 DN 123:193271
 TI L-Phenylalanine and L-tyrosine degradative pathways in *Rhodococcus erythropolis*
 AU Suemori, Akio; Nakajima, Kenji; Kurane, Ryuichiro; Nakamura, Yoshihiro
 CS Natl. Inst. Biosci. Hum.-Technol., Tsukuba, 305, Japan
 SO Seimei Kogaku Kogyo Gijutsu Kenkyusho Kenkyu Hokoku (1995), 3(2), 33-6
 CODEN: SKGIEM; ISSN: 0919-5351
 DT Journal
 LA English
 AB *Rhodococcus erythropolis* strain S1 was shown to degrade L-phenylalanine via phenylpyruvate and **homogentisate** and L-tyrosine through **p-hydroxyphenylpyruvate**, **p-hydroxyphenylacetate**, and **homogentisate**, which were conducted from oxygen consumption with intact cells, thin layer chromatog., and high performance liq. chromatog. expts. These pathways are in good agreement with that obsd. in *Nocardia* sp. and *Streptomyces* sp. L-Phenylalanine and L-tyrosine would appear to be transaminated by arom. amino acid **oxidase**. Arom. amino acid **oxidase**, **p-hydroxyphenylacetate 1-hydroxylase**, and **homogentisate 1,2-dioxygenase** activities were inducible by L-tyrosine or L-phenylalanine in strain S1.
 IT 55326-44-8, **p-Hydroxyphenylacetate 1-hydroxylase**
 RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
 (in L-phenylalanine and L-tyrosine degradative pathways in *Rhodococcus erythropolis*)
 RN 55326-44-8 HCAPLUS
 CN Oxygenase, 4-hydroxyphenylacetate 1-mono- (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 156-38-7, **p-Hydroxyphenylacetic acid** 156-39-8, **p-Hydroxyphenylpyruvic acid** 451-13-8, **Homogentisic acid**
 RL: MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
 (L-phenylalanine and L-tyrosine degradative pathways in *Rhodococcus erythropolis*)
 RN 156-38-7 HCAPLUS
 CN Benzenepropionic acid, 4-hydroxy- (9CI) (CA INDEX NAME)




RN 156-39-8 HCAPLUS
 CN Benzenepropionic acid, 4-hydroxy-.alpha.-oxo- (9CI) (CA INDEX NAME)



RN 451-13-8 HCAPLUS
 CN Benzenepropionic acid, 2,5-dihydroxy- (9CI) (CA INDEX NAME)

MARX 09/582,402



=> d bib abs hitstr 2

L33 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2001 ACS

AN 1976:519378 HCAPLUS

DN 85:119378

TI Catabolism of L-tyrosine by the homoprotocatechuate pathway in Gram-positive bacteria

AU Spornins, Velta L.; Chapman, Peter J.

CS Coll. Biol. Sci., Univ. Minnesota, St. Paul, Minn., USA

SO J. Bacteriol. (1976), 127(1), 362-6

CODEN: JOBAAY

DT Journal

LA English

AB A metabolic pathway for L-tyrosine catabolism involves 3,4-dihydroxyphenylacetic acid (homoprotocatechuic acid) as substrate for fission of the benzene nucleus. Cell exts. of an organism tentatively identified as a Micrococcus possessed the enzymes required for degrading homoprotocatechuate to succinate and pyruvate, and stoichiometry was established for several of these reactions. When the required coenzymes were added, cell exts. degraded L-tyrosine to the ring-fission product of homoprotocatechuate 2,3-dioxygenase and also converted 4-hydroxyphenylpyruvic acid into 4-hydroxyphenylacetic acid. This compd., in turn, gave stoichiometric amts. of the ring-fission product of homoprotocatechuate by the action of a NADP-dependent 3-hydroxylase coupled with homoprotocatechuate 2,3-dioxygenase. Evidence is presented that this route for L-tyrosine catabolism is taken by 5 other gram pos. strains, including Micrococcus lysodeikticus and a species of Bacillus. Five other gram pos. bacteria from other genera employed the alternative homogentisate pathway.


IT 156-38-7 156-39-8

RL: RCT (Reactant)

(oxidn. of, by Micrococcus, pathway of)


RN 156-38-7 HCAPLUS

CN Benzenecetic acid, 4-hydroxy- (9CI) (CA INDEX NAME)




RN 156-39-8 HCAPLUS

CN Benzenepropanoic acid, 4-hydroxy-.alpha.-oxo- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 1

L35 ANSWER 1 OF 20 HCAPLUS COPYRIGHT 2001 ACS
 AN 1999:374814 HCAPLUS
 DN 131:141884
 TI 4-hydroxybenzoic acid: a likely precursor of 2,4,6-tribromophenol in *Ulva lactuca*
 AU Flodin, Carina; Whitfield, Frank B.
 CS Food Science Australia, North Ryde, 1670, Australia
 SO Phytochemistry (1999), 51(2), 249-255
 CODEN: PYTCAS; ISSN: 0031-9422
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 AB The green marine alga *Ulva lactuca* is known to contain simple bromophenols, esp. 2,4,6-tribromophenol, but the precursor of these compds. in the alga is not known. With the aim of identifying potential precursors, the alga was analyzed for the presence of phenolic compds. The compds. identified by gas chromatog.-mass spectrometry were phenol, 4-hydroxybenzoic acid, 4-hydroxyphenylacetic acid, 4-hydroxyphenyllactic acid, 4-hydroxybenzaldehyde, 3,5-dibromo-4-hydroxybenzoic acid and 2,4,6-tribromophenol. Free L-tyrosine and free L-phenylalanine were also present in the alga. Furthermore, a crude enzyme ext. from the alga, which contained **bromoperoxidases**, was used to brominate a range of phenolic compds. and the formation of bromophenols was monitored. The compds. forming 2,4,6-tribromophenol were phenol, 4-hydroxybenzoic acid, 4-hydroxyphenylacetic acid, 4-hydroxybenzyl alc. and 2-hydroxybenzyl alc. 4-Hydroxybenzoic acid is designated as the most likely precursor of 2,4,6-tribromophenol in *U. lactuca* and a pathway for its formation from L-tyrosine, via 4-hydroxyphenylpyruvic acid, is proposed.
 IT 156-38-7, 4-Hydroxyphenylacetic acid
 RL: BSU (Biological study, unclassified); BIOL (Biological study)
 (4-hydroxybenzoic acid: likely precursor of 2,4,6-tribromophenol in *Ulva lactuca*)
 RN 156-38-7 HCAPLUS
 CN Benzeneacetic acid, 4-hydroxy- (9CI) (CA INDEX NAME)



RE.CNT 12


RE

- (1) Butler, A; Chem Rev 1993, V93, P1937 HCAPLUS
 - (4) Heimler, D; Chromatographia 1994, V38, P475 HCAPLUS
 - (5) Hewson, W; J Phycol 1980, V16, P340 HCAPLUS
 - (6) Landymore, A; Phycologia 1978, V17, P319 HCAPLUS
 - (7) Manley, S; FEBS Lett 1978, V93, P97 HCAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> d bib abs hitstr 2

L35 ANSWER 2 OF 20 HCAPLUS COPYRIGHT 2001 ACS
 AN 1998:455961 HCAPLUS
 DN 129:185307
 TI Conversion of tyrosine to phenolic derivatives by Taiwan cobra venom
 AU Nucaro, Elvira; Jodra, Maite; Russell, Emma; Anderson, Lois; Dennison, Philip; Dufton, Mark
 CS Dep. Pure Appl. Chem., Univ. Strathclyde, Glasgow, G1 1XL, UK
 SO Toxicicon (1998), 36(8), 1173-1187
 CODEN: TOXIA6; ISSN: 0041-0101
 PB Elsevier Science Ltd.
 DT Journal
 LA English
 AB We have examd. the ability of Taiwan cobra (*Naja naja atra*) venom to transform in vitro the amino acid tyrosine to phenolic oxidn. products via **4-hydroxyphenylpyruvate**. This amino acid can be released from neuropeptide substrates by oligopeptidases present in the venom. Using a variety of anal. techniques to probe a complicated series of reactions, we confirm that the L-amino acid **oxidase** present in the venom initially releases the keto form of **4-hydroxyphenylpyruvic acid** and hydrogen peroxide after reacting with the tyrosine. Thereafter, there is evidence that a tautomerase in the venom promotes a partial conversion of the keto-form **4-hydroxyphenylpyruvic acid** into an enol form. The enol is oxidized primarily to 4-hydroxybenzaldehyde and 4-hydroxyphenylacetic acid by the hydrogen peroxide co-released by the L-amino acid **oxidase**. The venom promotes both these spontaneous oxidn. routes and also generates traces of other phenolics, some of which are as yet unidentified. We propose that reactions between the precursors of the major oxidn. products may be responsible for generating unusual short-lived phenolics, possibly giving rise to special bioactivities that are relevant to venom action.

IT 156-38-7, 4-Hydroxyphenylacetic acid 156-39-8
 RL: MFM (Metabolic formation); BIOL (Biological study); FORM (Formation, nonpreparative)
 (conversion of tyrosine to phenolic derivs. by Taiwan cobra venom)
 RN 156-38-7 HCAPLUS
 CN Benzenecetic acid, 4-hydroxy- (9CI) (CA INDEX NAME)




RN 156-39-8 HCAPLUS
 CN Benzenepropanoic acid, 4-hydroxy-.alpha.-oxo- (9CI) (CA INDEX NAME)




=> d bib abs hitstr 3

L35 ANSWER 3 OF 20 HCAPLUS COPYRIGHT 2001 ACS
 AN 1990:104435 HCAPLUS
 DN 112:104435
 TI Isolation and characterization of surfactant degrading **bacteria**
 in a marine environment
 AU Sigoillot, Jean Claude; Nguyen, Marie Helene
 CS Lab. Microbiol., Fac. Sci. Tech. Saint-Jerome, Marseille, 13397, Fr.
 SO FEMS Microbiol. Ecol. (1990), 73(1), 59-67
 CODEN: FMECEZ; ISSN: 0168-6496
 DT Journal
 LA English
 AB Seawater and sediment samples from near the coasts of Hyeres Bay, France,
 were used for anionic surfactant titrns. with surface and bottom waters
 and the finest part of sediments. The capacity for surfactant degrdn. by
 the in situ microflora was evaluated. Using a selective plating
 technique, 26 strains able to utilize anionic surfactant were isolated
 from the selected **bacterial** communities. Their ability to
 degrade anionic surfactants was verified according to the biodegrdn. std.
 method. Isolated strains were characterized by morphol. and physiol.
 properties using the API 20 NE micro-method. All tested strains were Gram
 neg., strictly aerobic, rod or helical shaped. Their weak utilization of
 phenolic substrates suggests that they degrade preferentially the alkyl
 chain of the surfactant mol. Biodegrdn. was more efficient with
bacterial communities rather than with any isolated strains. Such
 observations indicate that complete mineralization involves several other
 so far nonisolated strains which complete the degrdn. initiated by the
 isolated strains.
 IT 156-38-7, 4-Hydroxyphenyl acetic
 acid 156-39-8
 RL: BIOL (Biological study)
 (anionic surfactant biodegrdn. by marine **bacteria** in presence
 of)
 RN 156-38-7 HCAPLUS
 CN Benzeneacetic acid, 4-hydroxy- (9CI) (CA INDEX NAME)




RN 156-39-8 HCAPLUS
 CN Benzenepropanoic acid, 4-hydroxy-.alpha.-oxo- (9CI) (CA INDEX NAME)




=> d bib abs hitstr 4

L35 ANSWER 4 OF 20 HCAPLUS COPYRIGHT 2001 ACS
 AN 1989:494267 HCAPLUS
 DN 111:94267
 TI Urinary organic acid excretion by babies born before 33 weeks of gestation
 AU Walker, Valerie; Mills, Graham A.
 CS Univ. Southampton, Southampton, S09 4XY, UK
 SO Clin. Chem. (Winston-Salem, N. C.) (1989), 35(7), 1460-6
 CODEN: CLCHAU; ISSN: 0009-9147
 DT Journal
 LA English
 AB Using anal. procedures that are widely used by labs. investigating metabolic disorders, urinary org. acid excretion was investigated in premature neonates who were receiving the usual clin. care. The purpose of this study was to provide a basis for the diagnosis of inherited org. acid defects. One-hundred-twenty-seven random (untimed) urine samples collected weekly from 22 infants of 25-32 wk of gestation (median, 28 wk) were analyzed. A wide variety of org. acids was excreted. After oximation, they were extd. with EtOAc and Et2O, derivatized to trimethylsilyl forms, and analyzed by gas-liq. chromatog. on a nonpolar fused silica capillary column, with mass spectrometry for identification. Profiles for individual babies varied markedly on different occasions, reflecting their metabolic status and **bacterial** activity in the gut. There was no significant ketonuria. Three metabolites identified for the 1st time in urine from normal neonates were 2,3-butanediol, 3-hydroxy-2-butanone (acetoin), and 4-hydroxy-3-methoxyphenyllactic acid. Increased excretion of 4-hydroxyphenyllactic acid and other phenolic acids occurred during parenteral feeding.
 IT 156-38-7, 4-Hydroxyphenylacetic acid 156-39-8
 RL: BIOL (Biological study)
 (of urine, of human premature newborn)
 RN 156-38-7 HCAPLUS
 CN Benzenecetic acid, 4-hydroxy- (9CI) (CA INDEX NAME)




RN 156-39-8 HCAPLUS
 CN Benzenepropanoic acid, 4-hydroxy-.alpha.-oxo- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 5


L35 ANSWER 5 OF 20 HCAPLUS COPYRIGHT 2001 ACS
 AN 1986:569543 HCAPLUS
 DN 105:169543
 TI The origin of central and peripheral p-hydroxyphenylacetic acid in man and rats
 AU Karoum, Farouk
 CS Neuropsychiatry Branch, Natl. Inst. Ment. Health, Washington, DC, 20032, USA
 SO Neuropsychopharmacol. Trace Amines: Exp. Clin. Aspects, [Trace Amines Symp.], 2nd (1985), 433-50. Editor(s): Boulton, Alan A. Publisher: Humana, Clifton, N. J.
 CODEN: 55FHAA
 DT Conference
 LA English
 AB The effects of a no. of monoamine oxidase (MAO) inhibitors, 2 types of dopa decarboxylase inhibitors, and neomycin on the prodn. of p-hydroxyphenylacetic acid (PHPA) and catecholamine metabolites were evaluated in an attempt to det. the origin of central and peripheral PHPA in rats. Acute intragastric (I.G.) administration of pargyline as well as chronic I.G. carbidopa, .alpha.-methyldopa (dopa decarboxylase inhibitors), and neomycin treatments failed to reduce PHPA concn. in the brain and urine, suggesting minor roles of gut flora and endogenously produced p-tyramine (p-Ty) in the overall body prodn. of PHPA. Neomycin reduced p-Ty and increased PHPA excretion. The excretions of the catecholamine metabolites phenylethylamine (PEA) and p-Ty excretions were altered according to the expected mode of action of the drugs employed. Paradoxically, carbidopa (like .alpha.-methyldopa) reduced hypothalamic norepinephrine and its metab., suggesting a central influence of carbidopa. Chronic administration of 3 types of MAO inhibitors, pargyline, clorgyline, and deprenyl, failed to reduced urine and brain PHPA. These drugs produced changes in PEA and catecholamine metabolite excretion and brain content that are consistent with effective inhibition of either or both MAO type A and B. Whereas body p-Ty is derived from p-tyrosine decarboxylation, most central and peripheral PHPA in rats and possibly man appears to originate from p-tyrosine transamination to p-hydroxyphenylpyruvic acid followed by decarboxylation to PHPA. The administration p-hydroxyphenylpyruvic acid elevated the excretion of PHPA as well as p-hydroxyphenyllactic acid and homogentisic acid. Blockade of p-tyrosine decarboxylation by carbidopa also elevated the excretion of deuterated PHPA derived from administered deuterated p-tyrosine, adding support to the above conclusion. The contribution of p-Ty metab. towards total body output of PHPA is <30%. The role of the gut flora in the prodn. of PEA and catecholamine metabolites appears to be minor. p-Ty was almost completely excreted in rats in the conjugated form. In contrast most urine PHPA (.apprx.80%) and PEA (70-90%) are excreted unconjugated. It appears that the metab. and turnover rate of p-Ty cannot be assessed from the assay of PHPA.

IT 156-38-7
 RL: FORM (Formation, nonpreparative)
 (formation of, by brain and peripheral tissue, monoamine oxidase inhibition effect on)
 RN 156-38-7 HCAPLUS
 CN Benzenecetic acid, 4-hydroxy- (9CI) (CA INDEX NAME)




IT 156-39-8
 RL: BIOL (Biological study)
 (hydroxyphenylacetate formation from, by brain and peripheral tissue)
 RN 156-39-8 HCAPLUS
 CN Benzenepropanoic acid, 4-hydroxy-.alpha.-oxo- (9CI) (CA INDEX NAME)

MARX 09/582,402




=> d bib abs hitstr 6

L35 ANSWER 6 OF 20 HCAPLUS COPYRIGHT 2001 ACS
 AN 1986:144087 HCAPLUS
 DN 104:144087
 TI Flavin nucleotide-dependent 3-hydroxylation of 4-hydroxyphenylpropanoid
 carboxylic acids by particulate preparations from potato tubers
 AU Boniwell, Jeremy M.; Butt, Vernon S.
 CS Bot. Sch., Oxford Univ., Oxford, OX1 3RA, UK
 SO Z. Naturforsch., C: Biosci. (1986), 41(1-2), 56-60
 CODEN: ZNCBDA; ISSN: 0341-0382
 DT Journal
 LA English
 AB Particulate preps. from potato tubers, extd. in 4 mM 2-mercaptoethanol,
 catalyze the 3-hydroxylation of 4-hydroxyphenylpropanoid carboxylic acids,
 including p-coumaric acid and tyrosine, in the presence of NADH (or NADPH)
 and FAD (or FMN); ascorbate could not substitute for these electron
 donors. Among a range of 4-hydroxylated C6-C2 and C6-C1 compds. tested,
 only 4-hydroxyphenylacetic acid and p-cresol were hydroxylated. The
 hydroxylase was sensitive to KCN and diethyldithiocarbamate and showed
 some features of phenolase hydroxylation, but no DOPA **oxidase** or
 chlorogenic acid **oxidase** activity was exhibited under these
 conditions. The phenolase complex, which is confined to potato tuber
 particles, presumably catalyzes the hydroxylation in whole or part.
 Activation of enzymes for chlorogenic acid formation by exposure of tubers
 to light was obsd.
 IT 156-38-7 156-39-8
 RL: RCT (Reactant)
 (hydroxylation of, by potato tuber)
 RN 156-38-7 HCAPLUS
 CN Benzenecetic acid, 4-hydroxy- (9CI) (CA INDEX NAME)




RN 156-39-8 HCAPLUS
 CN Benzenepropanoic acid, 4-hydroxy-.alpha.-oxo- (9CI) (CA INDEX NAME)




=> d bib abs hitstr 7

L35 ANSWER 7 OF 20 HCAPLUS COPYRIGHT 2001 ACS
 AN 1985:519560 HCAPLUS
 DN 103:119560
 TI The degradation of 1-phenylalkanes by an oil-degrading strain of
 Acinetobacter lwoffii
 AU Amund, O. O.; Higgins, I. J.
 CS Biotechnol. Cent., Cranfield Inst. Technol., Cranfield/Bedford, MK43 0AL,
 UK
 SO Antonie van Leeuwenhoek (1985), 51(1), 45-56
 CODEN: ALJMAO; ISSN: 0003-6072
 DT Journal
 LA English
 AB An oil-degrading **bacterium** identified as A. lwoffii was isolated
 by elective culture on North Sea Forties crude oil from an activated
 sludge sample. It grew on a wide range of n-alkanes (C12-C28) and
 1-phenylalkanes, including 1-phenyldodecane, 1-phenyltridecane, and
 1-phenyltetradecane. The organism degraded 1-phenyldodecane to
 phenylacetic acid, which was further metabolized via homogentisic acid,
 whereas 1-phenyltridecane was transformed to trans-cinnamic and
 3-phenylpropionic acid, which were not further metabolized. Evidence is
 presented for a relationship between arom. amino acid catabolism and
 1-phenyldodecane degrdn. in this organism.
 IT 156-38-7 156-39-8
 RL: BIOL (Biological study)
 (in arom. amino acid metab., by Acinetobacter lwoffii)
 RN 156-38-7 HCAPLUS
 CN Benzeneacetic acid, 4-hydroxy- (9CI) (CA INDEX NAME)




RN 156-39-8 HCAPLUS
 CN Benzenepropanoic acid, 4-hydroxy-.alpha.-oxo- (9CI) (CA INDEX NAME)




=> d bib abs hitstr 8


L35 ANSWER 8 OF 20 HCAPLUS COPYRIGHT 2001 ACS
 AN 1983:569341 HCAPLUS
 DN 99:169341
 TI Effects of drugs on the rat striatal concentration of p-hydroxyphenylacetic acid
 AU Kobayashi, Kiyofumi; Sato, Fumiko; Shohmori, Toshikiyo
 CS Med. Sch., Okayama Univ., Okayama, Japan
 SO Neurosciences (Kobe, Jpn.) (1983), 9(1), 82-3
 CODEN: NUOCDO
 DT Journal
 LA Japanese
 GI



AB Chlorpromazine [50-53-3] or sulpiride [15676-16-1] at 20 mg/kg, i.p., had no significant effect on the p-hydroxyphenylacetic acid (I) [156-38-7] level in the brain striatum, but sulpiride at 100 mg/kg or pimozide [2062-78-4] at 30 mg/kg decreased it. Apomorphine [58-00-4] was without effect. The precursors .beta.-phenylethylamine [64-04-0] at 15 mg/kg and p-tyramine [51-67-2] at 50 mg/kg increased the I level, whereas the monoamine oxidase inhibitor pargyline [555-57-7] at 50 mg/kg decreased it 50%; 4-hydroxyphenylpyruvic acid [156-39-8] also decreased I, but to a lesser extent.
 IT 156-39-8
 RL: BIOL (Biological study)
 (hydroxyphenylacetic acid of brain striatum response to)
 RN 156-39-8 HCAPLUS
 CN Benzenepropanoic acid, 4-hydroxy-.alpha.-oxo- (9CI) (CA INDEX NAME)




IT 156-38-7
 RL: BIOL (Biological study)
 (of brain striatum, drugs effect on)
 RN 156-38-7 HCAPLUS
 CN Benzenoacetic acid, 4-hydroxy- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 9


L35 ANSWER 9 OF 20 HCAPLUS COPYRIGHT 2001 ACS
 AN 1982:62975 HCAPLUS
 DN 96:62975
 TI Benzene derivatives as bactericides, neoplasm inhibitors, and immune adjuvants
 PA Hayashi, Etaku, Japan
 SO Jpn. Kokai Tokkyo Koho, 16 pp.
 CODEN: JKXXAF
 DT Patent
 LA Japanese
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 56115716	A2	19810911	JP 1980-18336	19800216
GI	JP 02033011	B4	19900725		




AB The benzene derivs. (I) (R1 = H, OH, Ph, etc; R2 = H or OH; R3 = H, carboxy, alkoxy, etc.; R4 = H, OH, carboxy, etc.; R5 = H, OH, alkoxy, carboxy; R6 = H, OH, alkoxy, etc.) are bactericides, neoplasm inhibitors, and immune adjuvants. Thus, antibacterial activities of 37 compds. such as L(+)-mandelic acid [17199-29-0] against *Pseudomonas aeruginosa*, *Staphylococcus aureus*, etc. were demonstrated in mice by administering these drugs orally or i.m. at 0.01-1.0 mg prior to the inoculation of the bacteria. DL-4-hydroxy-3-methoxymandelic acid [2394-20-9] (0.1 Mg) inhibited adenoma-180 40% in mice, while homophthalic acid [89-51-0] (0.01-1.0 mg, s.c.) enhanced the immune activity of vaccine against *Salmonella*.

IT 156-38-7 156-39-8
 RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
 (bactericidal activity of)
 RN 156-38-7 HCAPLUS
 CN Benzenecetic acid, 4-hydroxy- (9CI) (CA INDEX NAME)



RN 156-39-8 HCAPLUS
 CN Benzenepropanoic acid, 4-hydroxy-.alpha.-oxo- (9CI) (CA INDEX NAME)



MARX 09/582,402

=> d bib abs hitstr 10

L35 ANSWER 10 OF 20 HCAPLUS COPYRIGHT 2001 ACS
AN 1981:439751 HCAPLUS
DN 95:39751
TI Tyrosine aminotransferase as the rate-limiting step for tyrosine
catabolism in isolated rat liver cells
AU Dickson, Alan J.; Marston, Fiona A. O.; Pogson, Christopher I.
CS Biol. Lab., Univ. Kent, Canterbury/Kent, CT2 9BT, Engl.
SO FEBS Lett. (1981), 127(1), 28-32
CODEN: FEBLAL; ISSN: 0014-5793
DT Journal
LA English
AB The metab. of tyrosine by tyrosine aminotransferase (TAT) was investigated
in hepatocytes in various exptl. conditions. The rate of release of $3H_2O$
from L-[side chain-2,3- $3H$]tyrosine was used as an index of TAT activity.
Tyrosine was metabolized at a rate of 0.103 $\mu\text{mol/min/g}$ dry cells.
Significant $3H_2O$ formation was obsd. after 5 min of incubation and this
synthesis remained linear, until after 2-4 h when decreases were noted.
Starved rats showed greater and adrenalectomized rats showed lower TAT
activity than controls. Exposure of the cells to glucagon and
triamcinolone lead to increased TAT activity. However, the effect on
tyrosine metab. was not nearly as pronounced. Perhaps the 2 hormones
cause a post-translational modification of TAT.
IT 78213-74-8
RL: BIOL (Biological study)
(tyrosine metab. by, of hepatocytes, tyrosine aminotransferase in
relation to)
RN 78213-74-8 HCAPLUS
CN Oxidase, p-hydroxyphenylpyruvate (9CI) (CA INDEX NAME)


*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

=> d ind 10


L35 ANSWER 10 OF 20 HCAPLUS COPYRIGHT 2001 ACS
 CC 13-2 (Mammalian Biochemistry)
 Section cross-reference(s): 2, 18
 ST tyrosine aminotransferase hepatocyte glucagon triamcinolone; inanition
 liver tyrosine aminotransferase
 IT Michaelis constant
 (of tyrosine aminotransferase)
 IT Inanition
 (tyrosine aminotransferase of hepatocytes in)
 IT Adrenal gland
 (tyrosine aminotransferase of hepatocytes in relation to)
 IT Liver, metabolism
 (hepatocyte, tyrosine aminotransferase of, tyrosine metab. by)
 IT 60-18-4, biological studies
 RL: BPR (Biological process); BIOL (Biological study); PROC (Process)
 (metab. of, by tyrosine aminotransferase of hepatocytes)
 IT 124-94-7 9007-92-5, biological studies
 RL: BIOL (Biological study)
 (tyrosine aminotransferase of hepatocytes in response to)
 IT 9014-55-5
 RL: BIOL (Biological study)
 (tyrosine metab. by, of hepatocytes)
 IT 78213-74-8
 RL: BIOL (Biological study)
 (tyrosine metab. by, of hepatocytes, tyrosine aminotransferase in
 relation to)

=> d bib abs hitstr 11

L35 ANSWER 11 OF 20 HCAPLUS COPYRIGHT 2001 ACS
 AN 1981:436227 HCAPLUS
 DN 95:36227
 TI Inhibition of hydrogen peroxide generation in rat liver mitochondria by radical quenchers and phenolic compounds
 AU Swaroop, Anand; Ramasarma, T.
 CS Dep. Biochem., Indian Inst. Sci., Bangalore, 560 012, India
 SO Biochem. J. (1981), 194(3), 657-65
 CODEN: BIJOAK; ISSN: 0306-3275
 DT Journal
 LA English
 AB Scavengers of O₂-.bul. and OH.bul. inhibited generation of H₂O₂ by rat liver mitochondria with choline, glycerol 1-phosphate, and proline as substrates in high-concn. phosphate (or sulfate) buffer; ATP [56-65-5], ADP [58-64-0], thyronine derivs., and a no. of phenolic compds. were also potent inhibitors of H₂O₂ generation whereas Ph compds. had no effect. Phenolic compds. did not have any effect on mitochondrial superoxide dismutase and choline dehydrogenase activities nor on O₂-.bul. generation by the xanthine-xanthine oxidase system. Inhibition by phenolic compds. may have potential for regulation of the intracellular concn. of H₂O₂ which is considered to have a 2nd messenger function.
 IT 156-38-7 156-39-8
 RL: BIOL (Biological study)
 (hydrogen peroxide generation by liver mitochondria response to)
 RN 156-38-7 HCAPLUS
 CN Benzenecetic acid, 4-hydroxy- (9CI) (CA INDEX NAME)




RN 156-39-8 HCAPLUS
 CN Benzenepropanoic acid, 4-hydroxy-.alpha.-oxo- (9CI) (CA INDEX NAME)




=> d bib abs hitstr 12

L35 ANSWER 12 OF 20 HCAPLUS COPYRIGHT 2001 ACS
 AN 1980:109663 HCAPLUS
 DN 92:109663
 TI Tyrosyluria in marasmus
 AU Dhatt, P. S.; Saini, A. S.; Gupta, Indu; Mehta, H. C.; Singh, Harjit
 CS Dep. Paediatr., Med. Coll., Rohtak, India
 SO Br. J. Nutr. (1979), 42(3), 387-90
 CODEN: BJNUAV; ISSN: 0007-1145
 DT Journal
 LA English
 AB High levels of p-hydroxyphenyl acetic acid (I) [156-38-7] were excreted by 20 age-matched controls that did not exhibit conventional tyrosyluria, whereas in 30 patients with marasmus, plasma tyrosine [60-18-4] and urinary I and p-hydroxyphenyl lactic acid (II) [306-23-0] levels were higher than in controls. Conventional tyrosyluria was exhibited by 4 (13.3%) marasmus patients, and 16 (53.3%) patients had high I excretion. Ascorbic acid [50-81-7] (250 mg/day for 7 days) reduced II excretion but had no effect on I excretion. Thus, tyrosyluria in marasmus is probably due to reduced activity of hepatic p-hydroxyphenyl pyruvic acid oxidase (EC 1.13.11.27) [9029-72-5] due to the deficiency of ascorbate, and high excretion of I is probably related to age and nutrition of the child and unaffected by ascorbate administration. Urinary excretion of II is apparently a reliable index of tyrosyluria.
 IT 156-38-7
 RL: PROC (Process)
 (excretion of, in marasmus, tyrosyluria in relation to)
 RN 156-38-7 HCAPLUS
 CN Benzeneacetic acid, 4-hydroxy- (9CI) (CA INDEX NAME)




=> d bib abs hitstr 13

L35 ANSWER 13 OF 20 HCAPLUS COPYRIGHT 2001 ACS
 AN 1977:580481 HCAPLUS
 DN 87:180481
 TI The catabolism of L-tyrosine by an **Arthrobacter** sp
 AU Blakley, E. R.
 CS Prairie Reg. Lab., Natl. Res. Counc. Canada, Saskatoon, Sask., Can.
 SO Can. J. Microbiol. (1977), 23(9), 1128-39
 CODEN: CJMIAZ
 DT Journal
 LA English
 AB An **Arthrobacter** species metabolizes L-tyrosine by a pathway involving 3,4-dihydroxyphenylacetate as a key intermediate. P-Hydroxyphenylpyruvate is formed from tyrosine by an aminotransferase specifically requiring .alpha.-ketoglutarate for activity, and is then converted to p-hydroxyphenylacetate by an oxidative decarboxylation. P-Hydroxyphenylacetaldehyde is not an intermediate in the formation of p-hydroxyphenylacetate. Exts. of the **bacterium** oxidize 3,4-dihydroxyphenylacetate to .delta.-carboxymethyl-.alpha.-hydroxymuconic acid which, when supplemented with 2 mol. of NAD+, results in the prodn. of stoichiometric amts. of succinate and pyruvate.
 IT 156-38-7 156-39-8
 RL: FORM (Formation, nonpreparative)
 (formation of, from tyrosine, by **Arthrobacter**)
 RN 156-38-7 HCAPLUS
 CN Benzeneacetic acid, 4-hydroxy- (9CI) (CA INDEX NAME)




RN 156-39-8 HCAPLUS
 CN Benzenepropanoic acid, 4-hydroxy-.alpha.-oxo- (9CI) (CA INDEX NAME)




=> d bib abs hitstr 14

L35 ANSWER 14 OF 20 HCAPLUS COPYRIGHT 2001 ACS
AN 1974:447880 HCAPLUS
DN 81:47880
TI Metabolism of tritium-labeled tyrosine in the cerebrospinal fluid of cat.
Role of transamination
AU Guldberg, Ann M. R.; Guldberg, H. C.
CS Med. Sch., Univ. Bergen, Bergen, Norway
SO Neuropharmacology (1973), 12(12), 1135-44
CODEN: NEPHBW
DT Journal
LA English
AB p-Hydroxyphenylacetic acid and p-hydroxyphenyllactic acid were detected in the cerebrospinal fluid (CSF) of cats after intracisternal administration of 3H-labeled L-tyrosine (I), possibly resulting from transamination of I through the p-hydroxyphenylpyruvate pathway. Pretreatment of cats with the monoamine oxidase inhibitor, pargyline, did not alter the CSF level of p-hydroxyphenylacetic acid.
IT 156-38-7
RL: FORM (Formation, nonpreparative)
(formation of, as tyrosine metabolite in brain)
RN 156-38-7 HCAPLUS
CN Benzeneacetic acid, 4-hydroxy- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 15

L35 ANSWER 15 OF 20 HCAPLUS COPYRIGHT 2001 ACS
AN 1972:472409 HCAPLUS
DN 77:72409
TI Microbial conversion of p-hydroxyphenylacetic acid to homogentisic acid
AU Blakley, E. R.
CS Prairie Reg. Lab., Natl. Res. Counc. Canada, Saskatoon, Sask., Can.
SO Can. J. Microbiol. (1972), 18(8), 1247-55
CODEN: CJMIAZ
DT Journal
LA English
AB An unidentified **bacterium** degrades p-hydroxyphenylacetic acid by a pathway which involves homogentisic acid as an intermediate. Exts. of cells grown on p-hydroxyphenylacetic acid contain an enzyme that converts p-hydroxyphenylacetic acid to homogentisic acid. The enzyme has been partially purified by (NH₄)₂SO₄ fractionation and some of its properties examd. The complete oxidn. of 1 mole of p-hydroxyphenylacetic acid requires 1 mole of NADH or NADPH, and 1 mole of O, and results in the production of 1 mole of homogenetic acid. The enzyme prepn. has a high specificity for p-hydroxyphenylacetic acid, but has about 25% activity with p-hydroxyphenylpyruvic acid.
IT 156-38-7
RL: BIOL (Biological study)
(homogentisic acid formation from, by **bacteria**)
RN 156-38-7 HCAPLUS
CN Benzeneacetic acid, 4-hydroxy- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 16

L35 ANSWER 16 OF 20 HCAPLUS COPYRIGHT 2001 ACS

AN 1972:12169 HCAPLUS

DN 76:12169

TI Metabolism of tyrosine to p-hydroxyphenylpropionic acid and to p-hydroxyphenylacetic acid by the hemolymph of the american cockroach

AU Mills, Richard R.; Lake, C. Raymond

CS Dep. Biol., Tulane Univ., New Orleans, La., USA

SO Insect Biochem. (1971), 1(3), 264-70

CODEN: ISBCAN

DT Journal

LA English

AB Labeled tyrosine-U-14C was metabolized through 2 different pathways: tyrosine .fwdarw. p-hydroxy-phenylpyruvic acid .fwdarw. p-hydroxyphenylacetic acid and tyrosine .fwdarw. p-hydroxyphenylpyruvic acid .fwdarw. p-hydroxyphenyl-lactic acid .fwdarw. p-hydroxyphenylpropionic acid. These reactions took place in vitro using partially purified enzymes from whole hemolymph. The purification procedure involved column chromatog. on Sepharose 6B which effectively eliminated tyrosinase-phenoloxidase participation via removal of necessary cofactors and (or) activators. Tyrosine decarboxylase is in competition for the substrate since pyridoxal phosphate is an essential cofactor for both this enzyme and the synthesis of the 4 acids. Subsequent .beta.-hydroxylation of tyramine can be inhibited by the deletion of ascorbic acid from the reaction mixt. The synthesis of the acids can be obtained by using hemolymph from newly ecdysed larvae, intraecdysal larvae, and adult female cockroaches. Thus the enzyme system is present throughout the life of the insect and the synthesis is not switched off during ecdysis as it is in blowflies.


IT 156-38-7

RL: FORM (Formation, nonpreparative)

(formation of, from tyrosine by cockroach hemolymph)

RN 156-38-7 HCAPLUS

CN Benzenecetic acid, 4-hydroxy- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 17

L35 ANSWER 17 OF 20 HCAPLUS COPYRIGHT 2001 ACS

AN 1970:130358 HCAPLUS

DN 72:130358

TI Metabolism of phenolic compounds in hepatic diseases with encephalopathic effects

AU Ruge, W.; Otto, P.

CS Med. Klin., Hannover, Ger.

SO Verh. Deut. Ges. Inn. Med. (1969), 75, 329-32

CODEN: VDGIA2

DT Journal

LA German


AB In 20 patients with hepatic insufficiency, of which 15 showed encephalopathic symptoms, the following parameters were measured: serum tyrosine, serum and urine free phenol, and serum phenolic compds. (neutral phenols, phenolic amines, and phenolic acids). The phenolic acids were sep'd. by gas chromatog. after Me ester formation. p-Hydroxyphenylacetic acid and p-hydroxyphenylpyruvic acid are significantly increased in the comatose state, esp. after massive protein loading as produced in massive esophageal or gastric bleeding varices. In liver insufficiency a pos. correlation existed between p-hydroxyphenyl acids and free phenol, tyrosine, and ammonia N in serum. A neg. correlation existed in the Hb content of the blood. The m-hydroxyphenyl acids in the urine arose in great part from the action of bacterial enzymes in the gut on catechol amines. When patients received oral antibiotics these were greatly reduced in the urine.

IT 156-38-7 156-39-8

RL: BIOL (Biological study)
(of blood serum, in hepatic coma)


RN 156-38-7 HCAPLUS

CN Benzenecetic acid, 4-hydroxy- (9CI) (CA INDEX NAME)



RN 156-39-8 HCAPLUS

CN Benzenepropanoic acid, 4-hydroxy-.alpha.-oxo- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 18

L35 ANSWER 18 OF 20 HCAPLUS COPYRIGHT 2001 ACS

AN 1970:19718 HCAPLUS

DN 72:19718

TI Degradation of tyrosine by rat cecal contents

AU Bakke, Olav M.

CS Dep. Pharmacol., Univ. Bergen, Bergen, Norway

SO Scand. J. Gastroenterol. (1969), 4(7), 603-8

CODEN: SJGRA4

DT Journal

LA English

AB p-Cresol and phenol were the only simple phenols produced from tyrosine during anaerobic incubation with rat cecal contents, and the addn. of neomycin sulphate nearly abolished their formation. 4-Hydroxyphenylacetic acid and phloretic acid were the only phenolic acids detected. The former compd. was decarboxylated to p-cresol while phloretic acid did not yield simple phenols. Because of extensive decarboxylation of 4-hydroxybenzoic acid the failure to detect this compd. does not exclude it as an immediate precursor of p henol in the incubates with tyrosine added. 4-Hydroxyphenylpyruvic acid and p-coumaric acid were not detected in these incubates, and there was no evidence of microbial metabolism of 4-ethylphenol and p-cresol.


IT 156-38-7

RL: FORM (Formation, nonpreparative)

(formation of, from tyrosine by cecal contents)

RN 156-38-7 HCAPLUS

CN Benzeneacetic acid, 4-hydroxy- (9CI) (CA INDEX NAME)




=> d bib abs hitstr 19

L35 ANSWER 19 OF 20 HCAPLUS COPYRIGHT 2001 ACS
 AN 1969:54884 HCAPLUS
 DN 70:54884
 TI Biosynthesis and metabolism of hydroxyphenylacetic acids in higher plants
 AU Kindl, Helmut
 CS Univ. Wien, Vienna, Austria
 SO Eur. J. Biochem. (1969), 7(3), 340-7
 CODEN: EJBCAI
 DT Journal
 LA English
 AB 2-Hydroxyphenylacetic acid, a natural phenolic product found in the genus *Astilbe*, comes from the shikimic acid pathway via phenylpyruvic acid. The existence of 2 routes for the biosynthesis of 2-hydroxyphenylacetic acid could be demonstrated. A direct transformation of phenylpyruvic acid into 2-hydroxyphenylacetic acid occurred involving a migration of the side chain. More than 95% of the T activity of 2-hydroxyphenylacetic acid was localized in position 5 when L-phenylalanine-4-3H was fed. This complex oxidn. is analogous to the known conversion of 4-hydroxyphenylpyruvic acid to homogentisic acid. A hydroxylation of phenylacetic-4-3H acid to 2-hydroxyphenylacetic-4-3H acid was observed in vivo, and was also found to take place in vitro, utilizing the system peroxidase-enediol-02. 2,3-Dihydroxy-phenylacetic acid and 2-hydroxy-3-methoxyphenylacetic acid could be established as natural products occurring in higher plants. Their chem. synthesis is described. By feeding expts. the following metabolic pathway is suggested: 2-hydroxyphenylacetic acid .fwdarw. 2,3-dihydroxyphenylacetic acid .fwdarw. 2-hydroxy-3-methoxyphenylacetic acid. 3,4-Dihydroxyphenylacetic acid and 3-methoxy-4-hydroxyphenylacetic acid were detected in exts. from various species of *Astilbe* and identified by paper chromatog. These 2 acids are metabolic products of 4-hydroxyphenylacetic acid. Expts. with shikimic-U-14C acid and DL-phenylalanine-.alpha.-14C seem to indicate that the regulation of the biosynthesis of 2-hydroxyphenylacetic acid and 4-hydroxyphenylacetic acid takes place on the level of prephenic acid. Preliminary results were obtained consistent with the hypothesis that in *A. chinensis* the 2,3-dihydroxyphenylacetic acid, 3,4-dihydroxyphenylacetic acid, and 2,5-dihydroxyphenylacetic acid are further metabolized and can be degraded by ring cleavage.

IT 156-38-7
 RL: FORM (Formation, nonpreparative)
 (formation of, pathway in *Astilbe chinensis* for)

RN 156-38-7 HCAPLUS
 CN Benzeneacetic acid, 4-hydroxy- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 20

L35 ANSWER 20 OF 20 HCAPLUS COPYRIGHT 2001 ACS

AN 1968:11093 HCAPLUS

DN 68:11093

TI Investigation in vivo of the biochemical defect in hereditary tyrosinemia and tyrosyluria

AU Scriver, Charles R.; Davies, Eluned

SO Can. Med. Assoc. J. (1967), 97(18), 1076-8.

CODEN: CMAJAX

DT Journal

LA English

AB The nature of tyrosyluria (urinary excretion of Millon-pos. derivs., viz., p-hydroxyphenylpyruvate (p-HPPA), p-hydroxyphenyllactate (pHPLA), p-hydroxyphenylacetate (pHPAA), and tyrosine) was studied. Restriction of dietary tyrosine suppressed urinary excretion of these compds. Investigation of the reversible inhibition of the enzyme pHPAA oxidase by consecutive administration of ascorbic acid, 500 mg. daily for 3 days, folic acid, 5 mg. twice daily i.m. for 3 days, and hydrocortisone, 50 mg. twice daily i.m. for 3 days, showed no effect on tyrosyluria or tyrosinemia. With tyrosine loading (0.25 millimole/kg. before treatment), the augmented serum tyrosine was always accompanied by increased tyrosyluria which exceeded the preload excretion. With tyrosine load after 6 months on dietary therapy, the results were the same as before except that plasma tyrosine was normal and the degree of tyrosinemia was much less. With oral neomycin (500 mg. twice daily for 4 days), there was partial suppression of the augmented tyrosyluria. With pHPAA loading (0.25 millimole/kg. before treatment), augmented serum tyrosine and tyrosyluria occurred. With L-phenylalanine (0.60 millimole/kg. after 6 months on treatment), plasma tyrosine rose abnormally, and heavy tyrosyluria appeared in the 1st 6 hrs. Restriction of phenylalanine and tyrosine to 25% of the normal daily intake eliminated serum tyrosine and tyrosyluria; introduction of tyrosine resulted in immediate reappearance of tyrosyluria, and serum tyrosine reappeared the next day.


IT 156-38-7 156-39-8

RL: BIOL (Biological study)

(in urine in tyrosinemia and tyrosyluria)


RN 156-38-7 HCAPLUS

CN Benzenecetic acid, 4-hydroxy- (9CI) (CA INDEX NAME)



RN 156-39-8 HCAPLUS

CN Benzenepropanoic acid, 4-hydroxy-.alpha.-oxo- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 1

L41 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2001 ACS
 AN 1997:130949 HCAPLUS
 DN 126:248440
 TI Spectrophotometric determination of homogentisate using *Aspergillus nidulans* homogentisate dioxygenase
 AU Fernandez-Canon, Jose M.; Penalva, Miguel A.
 CS Dep. Microbiologia Molecular, Centro Investigaciones Biologicas CSIC, Madrid, 28006, Spain
 SO Anal. Biochem. (1997), 245(2), 218-221
 CODEN: ANBCA2; ISSN: 0003-2697
 PB Academic
 DT Journal
 LA English
 AB The presence of homogentisic acid (HGA) in urine is diagnostic for alkaptonuria, a classical example of a biochem. lesion resulting from a single gene trait. We describe here simple culture conditions which induce the synthesis of high levels of homogentisate dioxygenase activity in mycelia from the filamentous ascomycete *Aspergillus nidulans*. Crude enzyme preps., showing an apparent K_m of 9 μ M for homogentisate and an optimal pH of 6.5-7.0 are rather stable and highly specific for homogentisate. Thus, the reaction is not competed by a large molar excess of a no. of substrate structural analogs, including phenylacetate and its 2-, 3-, and 4-hydroxy derivs., phenylalanine, tyrosine, phenylpyruvate, and gentisate. We demonstrate how this enzyme prepn. can be used in sensitive, spectrophotometric enzymic detn. of this compd. The accuracy is almost indistinguishable from that obtained by HPLC. The method can be applied to routine detn. of homogentisate in human urine. A 1-L culture of the mold provides sufficient enzyme activity for 1500 enzymic assays.

=> d ind

L41 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2001 ACS
 CC 9-5 (Biochemical Methods)
 Section cross-reference(s): 7, 10, 14
 ST spectrophotometry homogentisate *Aspergillus nidulans* dioxygenase
 IT Metabolic diseases
 (alkaptonuria; spectrophotometric detn. of homogentisate using *Aspergillus nidulans* homogentisate dioxygenase)
 IT *Aspergillus nidulans*
 Mold (fungus)
 Urine analysis
 (spectrophotometric detn. of homogentisate using *Aspergillus nidulans* homogentisate dioxygenase)
 IT 451-13-8, Homogentisic acid
 RL: ANT (Analyte); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (spectrophotometric detn. of homogentisate using *Aspergillus nidulans* homogentisate dioxygenase)
 IT 9029-49-6P, **Homogentisate** dioxygenase
 RL: ARG (Analytical reagent use); **BPN (Biosynthetic preparation)**; ANST (Analytical study); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (spectrophotometric detn. of **homogentisate** using *Aspergillus nidulans* **homogentisate** dioxygenase)
 IT 60-18-4, Tyrosine, analysis 63-91-2, Phenylalanine, analysis 122-79-2, Phenylacetate 156-06-9 490-79-9 621-37-4 2848-25-1, 2-Hydroxyphenylacetate 3233-32-7, 4-Hydroxyphenylacetate
 RL: ARU (Analytical role, unclassified); ANST (Analytical study)
 (spectrophotometric detn. of homogentisate using *Aspergillus nidulans* homogentisate dioxygenase)

=> d bib abs hitstr 2

L41 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2001 ACS

AN 1995:796623 HCAPLUS

DN 123:333642

TI Molecular characterization of a gene encoding a homogentisate dioxygenase from *Aspergillus nidulans* and identification of its human and plant homologs

AU Fernandez-Canon, Jose M.; Penalva, Miguel A.

CS Dep. Microbiol. Mol., CSIC, Madrid, 28006, Spain

SO J. Biol. Chem. (1995), 270(36), 21199-205

CODEN: JBCHA3; ISSN: 0021-9258

DT Journal

LA English

AB The authors report here the first characterization of a gene encoding a homogentisate dioxygenase, the *Aspergillus nidulans* hmgA gene. The HmgA protein catalyzes an essential step in phenylalanine catabolism, and disruption of the gene results in accumulation of homogentisate in broths contg. phenylalanine. HmgA putatively encodes a 448-residue polypeptide (Mr = 50,168) contg. 21 histidine and 23 tyrosine residues. This polypeptide has been expressed in *Escherichia coli* as a fusion to glutathione S-transferase, and the affinity-purified protein has homogentisate dioxygenase activity. *A. nidulans*, an ascomycete amenable to classical and reverse genetic anal., is a good metabolic model to study inborn errors in human Phe catabolism. One such disease, alkaptonuria, was the first human inborn error recognized (Garrod, A. E. (1902) *Lancet* 2, 1616-1620) and results from loss of homogentisate dioxygenase. Here the authors take advantage of the high degree of conservation between the amino acid sequences of the fungal and higher eukaryote enzymes of this pathway to identify expressed sequence tags encoding human and plant homologues of HmgA. This is a significant advance in characterizing the genetic defect(s) of alkaptonuria and illustrates the usefulness of this fungal model.

=> d ind 2

L41 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2001 ACS

CC 7-5 (Enzymes)

Section cross-reference(s): 3, 10, 14

ST *Aspergillus* gene hmgA homogentisate dioxygenase sequence; human phenylalanine catabolism model system *Aspergillus*; alkaptonuria phenylalanine catabolism model system *Aspergillus*; expressed sequence tag human plant alkaptonuria

IT Transcription, genetic

(PhAc and Phe induced; mol. characterization of gene encoding homogentisate dioxygenase from *Aspergillus nidulans* and identification of its human and plant homologs)

IT Genetic element

RL: BOC (Biological occurrence); PRP (Properties); BIOL (Biological study); OCCU (Occurrence)

(expressed sequence-tag (EST), identification of human and plant HmgA; mol. characterization of gene encoding homogentisate dioxygenase from *Aspergillus nidulans* and identification of its human and plant homologs)

IT *Escherichia coli*

(expression and purifn. in; mol. characterization of gene encoding homogentisate dioxygenase from *Aspergillus nidulans* and identification of its human and plant homologs)

IT Gene, plant

RL: PRP (Properties)

(hmgA; mol. characterization of gene encoding homogentisate dioxygenase from *Aspergillus nidulans* and identification of its human and plant homologs)

IT *Aspergillus nidulans*

Deoxyribonucleic acid sequences

Protein sequences

(mol. characterization of gene encoding homogentisate dioxygenase from *Aspergillus nidulans* and identification of its human and plant

- homologs)
- IT Alkaptonuria
(significant advance in characterizing the genetic defect(s) of; mol. characterization of gene encoding homogentisate dioxygenase from *Aspergillus nidulans* and identification of its human and plant homologs)
- IT 170561-26-9P
RL: BPN (Biosynthetic preparation); PRP (Properties); PUR (Purification or recovery); BIOL (Biological study); PREP (Preparation)
(amino acid sequence; mol. characterization of gene encoding **homogentisate** dioxygenase from *Aspergillus nidulans* and identification of its human and plant homologs)
- IT 63-91-2, Phenylalanine, biological studies
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(catabolism, *Aspergillus nidulans* as system to study errors in human; mol. characterization of gene encoding homogentisate dioxygenase from *Aspergillus nidulans* and identification of its human and plant homologs)
- IT 9029-49-6, Homogentisate dioxygenase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(mol. characterization of gene encoding homogentisate dioxygenase from *Aspergillus nidulans* and identification of its human and plant homologs)
- IT 168857-03-2P, Genbank U30797
RL: BPN (Biosynthetic preparation); PRP (Properties); BIOL (Biological study); PREP (Preparation)
(nucleotide sequence; mol. characterization of gene encoding **homogentisate** dioxygenase from *Aspergillus nidulans* and identification of its human and plant homologs)

=> d bib abs hitstr 1

L42 ANSWER 1 OF 8 HCAPLUS COPYRIGHT 2001 ACS
AN 2001:332143 HCAPLUS
DN 134:321593
TI Protein and cDNA sequences of a human proteasome subunit .alpha. sequence
homolog (hPas) and uses thereof
IN Li, Nenggan; Xiao, Huasheng; Kang, Baiyu; Song, Huaidong; Chen, Zhu; Han,
Zheguang
PA South China Research Center, National Human Gene Group, Peop. Rep. China
SO Faming Zhuanli Shenqing Gongkai Shuomingshu, 20 pp.
CODEN: CNXXEV
DT Patent
LA Chinese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	CN 1271006	A	20001025	CN 2000-114949	20000317
AB	The invention provides protein and cDNA sequences of a novel human proteasome subunit .alpha. (hPas) which is a sequence homolog of Sulfolobus solfataricus Pas gene. The invention also relates to constructing hPas gene expression vectors to prep. recombinant hPas using E.coli cells or eukaryotic cells. The invention further relates to the uses of hPas. Methods of prepg. antibodies of recombinant human hPas are also described.				

=> d bib abs hitstr 2

L42 ANSWER 2 OF 8 HCAPLUS COPYRIGHT 2001 ACS

AN 2001:320060 HCAPLUS

DN 134:339179

TI Nucleic acids and proteins associated with cancer as antitumor targets

IN Burmer, Glenna C.; Brown, Joseph P.; Pritchard, David

PA Lifespan Biosciences, Inc., USA

SO PCT Int. Appl., 98 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1


	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001030964	A2	20010503	WO 2000-US29126	20001020
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			

PRAI US 1999-161232 P 19991022

AB This invention relates to the discovery of nucleic acids assocd. with cell proliferation, neoplasia, cell transformation, malignant tumor formation and metastasis and uses therefor. The present invention provides a method for cancer diagnosing by detecting the overexpression or the underexpression of a cancer-assocd. mRNA in the tissue of interest, preferably in liver, breast, prostate, kidney and colon. In another aspect, the invention provides methods for arresting cancer and a method for identifying a modulators of cancer development.

=> d bib abs hitstr 3

L42 ANSWER 3 OF 8 HCAPLUS COPYRIGHT 2001 ACS
 AN 2001:8060 HCAPLUS
 DN 134:307022
 TI Antibody-catalyzed hydrolysis of oligomeric esters: a model for the degradation of polymeric materials
 AU Brummer, Oliver; Hoffman, Timothy Z.; Chen, Da-Wei; Janda, Kim D.
 CS Department of Chemistry, The Scripps Research Institute and The Skaggs Institute for Chemical Biology, La Jolla, CA, 92037, USA
 SO Chem. Commun. (Cambridge) (2001), (1), 19-20
 CODEN: CHCOFS; ISSN: 1359-7345
 PB Royal Society of Chemistry
 DT Journal
 LA English
 AB A catalytic antibody has been discovered that degrades oligomeric ester substrates. All the observations and data confirmed that the antibody performed oligomer degrdns. by 'multimer' processing using nonregioselective, kinetically biased endo-cleavage, rather than a stepwise deoligomerization through cleavage of monomers from a terminus. These findings are of fundamental importance as now catalytic antibodies share another trait thought only to be assocd. with enzymes, the biodegrdn. of oligo and polymeric materials.
 IT 156-38-7P, 4-Hydroxyphenylacetic acid
 RL: BPN (Biosynthetic preparation); RCT (Reactant); BIOL (Biological study); PREP (Preparation)
 (discovery of catalytic antibody capable of degrading oligomeric ester substrates)
 RN 156-38-7 HCAPLUS
 CN Benzeneacetic acid, 4-hydroxy- (9CI) (CA INDEX NAME)




RE.CNT 14

RE

- (1) Albertsson, A; Acta Polym 1995, V46, P114 HCAPLUS
 - (2) Brummer, O; Tetrahedron Lett 1999, V40, P7307 HCAPLUS
 - (3) Copeland, R; Bioorg Med Chem Lett 1995, V5, P1947 HCAPLUS
 - (5) Janda, K; Comprehensive Supramolecular Chemistry 1996, V4, P43 HCAPLUS
 - (6) Jesudason, J; J Environ Polym Degrad 1993, V1, P89 HCAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitstr 4

L42 ANSWER 4 OF 8 HCAPLUS COPYRIGHT 2001 ACS
AN 2000:375847 HCAPLUS
DN 133:278482
TI Phytotoxins produced by Sclerotium fumigatum Nakata
AU Adachi, Takuo; Inagaki, Kimiharu; Yamada, Tetsuya
CS Research Laboratory of Natural Organic Chemistry, Meijo University, Japan
SO Meijo Daigaku Nogakubu Gakujutsu Hokoku (2000), 36, 33-37
CODEN: MDNGBZ; ISSN: 0910-3376
PB Meijo Daigaku Nogakubu
DT Journal
LA Japanese
AB The methylate of phytotoxins produced by Sclerotium futmigatum Nakata was
sepd. by GC-MS with DB-1 capillary column (30 m x 0.253 mm i.d.; 0.25
.mu.m film thickness). Four peaks were identified by mass spectra of
electron-impact ionization. Consequently, p-hydroxybenzoic acid,
phenylacetic acid, o-hydroxyphenyl acetic acid and p-hydroxyphenylacetic
acid were identified as the phytotoxins. These arom. acids were newly
identified as phytotoxins produced by S. funzigatum.
IT 156-38-7P, p-Hydroxyphenylacetic acid
RL: BPN (Biosynthetic preparation); BIOL (Biological study);
PREP (Preparation)
(phytotoxins produced by Sclerotium fumigatum Nakata)
RN 156-38-7 HCAPLUS
CN Benzeneacetic acid, 4-hydroxy- (9CI) (CA INDEX NAME)



=> d bib abs hitstr 5

L42 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2001 ACS

AN 1999:723147 HCAPLUS

DN 131:332967

TI Genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same

IN Ben-Artzi, Hanna; Ayal-HersHKovitz, Maty; Yacoby-Zeevi, Oron; Pecker, Iris; Peleg, Yoav; Shlomi, Yinon

PA Insight Strategy & Marketing Ltd., Israel; Friedman, Mark, M.

SO PCT Int. Appl., 118 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9957244	A1	19991111	WO 1999-US9256	19990429
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 9937705	A1	19991123	AU 1999-37705	19990429
EP 1076689	A1	20010221	EP 1999-920135	19990429
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
NO 2000005100	A	20001228	NO 2000-5100	20001010
PRAI US 1998-71618	A	19980501		
US 1999-260038	A	19990302		
WO 1999-US9256	W	19990429		

AB Bacterial, yeast and animal cells and methods for overexpressing recombinant heparanase in cellular systems, methods of purifying recombinant heparanase therefrom and modified heparanase species which serve as precursors for generating highly active heparanase by proteolysis. Heparanase is a glycosylated enzyme involved in catabolism of certain glycosaminoglycans, in tumor cell invasion and metastasis, and possibly in angiogenesis. It has potential therapeutic applications for viral infection, neurodegenerative diseases, restenosis, and atherosclerosis. A signal peptide was incorporated for effective protein secretion in yeast and bacteria and insect and mammalian cells. Protein secretion is achieved by induction by thrombin and calcium ionophores and immune complexes and antigens and mitogens. This work describes prodn. of heparanase on a biotechnol. scale of at least half a liter growth medium by affinity purifn. This large scale propagation of animal cells is described in a Spinner-basket bioreactor. The heparanase enzyme is activated by digestion with a protease such as cathepsin L or trypsin at appropriate pH. A correctly folded catalytically active heparanase is generated.

RE.CNT 2

RE

(1) Insight Strategy & Marketing Ltd; WO 9911798 A1 1999 HCAPLUS

(2) The Upjohn Co; WO 9504158 A1 1995 HCAPLUS

=> d ind 5

L42 ANSWER 5 OF 8 HCAPLUS COPYRIGHT 2001 ACS

IC ICM C12N001-21

ICS C12N001-15; C12N001-19; C12N005-10; C12N009-24; C12N015-09; C12N015-56; C12N015-63

CC 3-1 (Biochemical Genetics)

Section cross-reference(s): 7, 14

ST secretion heparanase human sequence cDNA purifn engineering; affinity chromatog heparanase human secretion engineering purifn

- IT Animal cell line
(293, good host expression system; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Animal cell line
(3T3, good host expression system; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Animal cell line
(BHK-21, good host expression system; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Animal cell line
(CHO, good host expression system; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Animal cell line
(COS, good host expression system; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Animal cell line
(Daudi, good host expression system; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Animal cell line
(Ehrlich ascites, good host expression system; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Insect (Insecta)
(High five and SF21; good host expression system; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Animal cell line
(L-929, good host expression system; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Animal cell line
(MDCK, good host expression system; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Animal cell line
(Mamalba cells and BLG cells; good host expression system; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Animal cell line
(Namalwa, good host expression system; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Animal cell line
(Raji, good host expression system; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Animal cell line
(SK-hep-1, good host expression system; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Animal cell line
(Vero, good host expression system; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT pH
(activation of heparanase enzyme by digestion with protease at appropriate pH; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Protein degradation
(applications for; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Protein folding
(generation of correctly folded heparanase; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)

- purifying same)
- IT Genetic engineering
 - Genetic vectors
 - Protein sequences
 - cDNA sequences
 - (genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Animal cell
 - Bacteria (Eubacteria)
 - Escherichia coli
 - HeLa cell
 - Komagataella pastoris
 - Pichia angusta
 - Saccharomyces cerevisiae
 - Yeast
 - (good host expression system; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Ion exchange liquid chromatography
 - (heparanase purifn. using Source-S column; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Antibodies
 - RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 - (heparanase-specific; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Gene, microbial
 - RL: **BPN (Biosynthetic preparation)**; IMF (Industrial manufacture); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 - (hpa; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Antibodies
 - RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 - (immobilized; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Signal peptides
 - RL: BPN (Biosynthetic preparation); BUU (Biological use, unclassified); BIOL (Biological study); PREP (Preparation); USES (Uses)
 - (incorporation of signal peptide for protein secretion; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Recombination, genetic
 - (integration, stable transduction by integration; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Mitogens
 - (ionophore; protein secretion induction by use of; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Antigens
 - Immune complexes
 - RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BIOL (Biological study); PROC (Process)
 - (ionophore; protein secretion induction by use of; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Animal cell
 - (mammalian, good host expression system; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Yeast
 - (methylophilic, good host expression system; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Secretion (process)
 - (protein; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT DNA

- RL: BPN (Biosynthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(recombinant; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Transduction, genetic
(stable transduction by integration; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT Bioreactors
(utilization of Spinner-basket bioreactor; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT 9001-92-7, Protease 37259-58-8, Serine protease 37353-41-6, Cysteine protease 78169-47-8, Aspartyl protease 81669-70-7, Metalloproteinase
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(activation of heparanase enzyme by digestion with protease; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT 37205-61-1, Protease inhibitor
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BUU (Biological use, unclassified); BIOL (Biological study); PROC (Process); USES (Uses)
(administration of inhibitor to stop processing of heparanase; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT 221113-49-1P, Heparanase (human gene *hpa*)
RL: BPN (Biosynthetic preparation); IMF (Industrial manufacture); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT 89800-66-8P, Heparanase
RL: BPN (Biosynthetic preparation); IMF (Industrial manufacture); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT 7440-70-2, Calcium, biological studies 16561-29-8, Phorbol 12-myristate 13-acetate 52665-69-7, Calcimycin
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BIOL (Biological study); PROC (Process)
(ionophore; protein secretion induction by use of; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT 221113-46-8P
RL: BPN (Biosynthetic preparation); IMF (Industrial manufacture); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(nucleotide sequence; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT 9002-04-4, Thrombin
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BIOL (Biological study); PROC (Process)
(protein secretion induction by use of; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT 9002-07-7, Trypsin 60616-82-2, Cathepsin L
RL: BUU (Biological use, unclassified); BIOL (Biological study); USES (Uses)
(proteolytic processing of heparanase by trypsin and cathepsin L; genetically modified cells and methods for expressing recombinant heparanase and methods of purifying same)
- IT 249925-81-3, PN: WO9957244 SEQID: 4 unclaimed DNA 249925-83-5, PN: WO9957244 SEQID: 5 unclaimed DNA 249925-84-6, PN: WO9957244 SEQID: 6 unclaimed DNA 249925-85-7, PN: WO9957244 SEQID: 7 unclaimed DNA 249925-86-8, PN: WO9957244 SEQID: 8 unclaimed DNA 249925-87-9, PN: WO9957244 SEQID: 9 unclaimed DNA 249925-88-0, PN: WO9957244 SEQID: 10 unclaimed DNA 249925-89-1, PN: WO9957244 SEQID: 11 unclaimed DNA

249925-90-4, PN: WO9957244 SEQID: 12 unclaimed DNA 249925-91-5, PN:
WO9957244 SEQID: 15 unclaimed DNA 249925-92-6, PN: WO9957244 SEQID: 16
unclaimed DNA 249925-93-7, PN: WO9957244 SEQID: 17 unclaimed DNA
249925-94-8, PN: WO9957244 SEQID: 18 unclaimed DNA 249925-95-9, PN:
WO9957244 SEQID: 19 unclaimed DNA 249925-96-0, PN: WO9957244 SEQID: 20
unclaimed DNA 249925-98-2, PN: WO9957244 SEQID: 21 unclaimed DNA
249925-99-3, PN: WO9957244 SEQID: 22 unclaimed DNA 249926-01-0, PN:
WO9957244 SEQID: 23 unclaimed DNA 249926-02-1, PN: WO9957244 SEQID: 24
unclaimed DNA
RL: PRP (Properties)
(unclaimed nucleotide sequence; genetically modified cells and methods
for expressing recombinant heparanase and methods of purifying same)
IT 54017-28-6 91859-00-6 249744-02-3
RL: PRP (Properties)
(unclaimed sequence; genetically modified cells and methods for
expressing recombinant heparanase and methods of purifying same)

=> d bib abs hitstr 6

L42 ANSWER 6 OF 8 HCAPLUS COPYRIGHT 2001 ACS
 AN 1999:492740 HCAPLUS
 DN 132:48655
 TI Rapid phenotyping of HPA-1a using either diabody-based hemagglutination or recombinant IgG1-based assays
 AU Watkins, N. A.; Armour, K. L.; Smethurst, P. A.; Metcalfe, P.; Scott, M. L.; Hughes, D. L.; Smith, G. A.; Williamson, L. M.; Clark, M. R.; Ouwehand, W. H.
 CS Division of Transfusion Medicine, Department of Haematology, and the Division of Immunology, Department of Pathology, University of Cambridge, Cambridge, CB2 2PT, UK
 SO Transfusion (Bethesda, Md.) (1999), 39(7), 781-789
 CODEN: TRANAT; ISSN: 0041-1132
 PB American Association of Blood Banks
 DT Journal
 LA English
 AB The HPA-1 system is carried on the .beta.3 integrin. HPA-1a (Zwa, PlA1) is immunogenic in an HPA-1b homozygote (HPA-1b1b). In pregnancy, 1 of 365 women forms anti-HPA-1a, which causes severe thrombocytopenia in 1 in 1100 neonates. Identification of women at risk of forming anti-HPA-1a and the screening of donors to obtain HPA-1a-neg. platelets for therapy need reliable, low-cost, automated assays. A diabody with dual specificity for HPA-1a .times. D and and IgG1 anti-HPA-1a have been constructed by the use of the genes encoding the first anti-HPA-1a fragment. With these reagents, two complementary HPA-1a phenotyping assays have been developed. This diabody was used in a simple hemagglutination technique to perform HPA-1a phenotyping on sol. glycoprotein IIb/IIIa from EDTA plasma samples. Over 1000 unselected donors have been correctly HPA-1a-phenotyped by use of the diabody. The human recombinant IgG1 anti-HPA-1a was produced in a rat myeloma cell line and was fluorescein labeled for use in a whole-blood flow cytometric HPA-1a phenotyping assay. This IgG1 anti-HPA-1a shows a clear differential between HPA-1a-pos. and HPA-1a-neg. platelets at nM antibody concns. The two recombinant reagents described are highly suitable for screening and confirmatory HPA-1a phenotyping. They permit rapid detn. of the HPA-1a phenotype and are amenable to automation.

RE.CNT 33
 RE
 (2) Bessos, H; Br J Haematol 1996, V92, P221 HCAPLUS
 (3) Brennan, M; Science 1985, V229, P81 HCAPLUS
 (4) Bye, J; J Clin Invest 1992, V90, P2481 HCAPLUS
 (8) Griffin, H; Blood 1995, V86, P4430 HCAPLUS
 (9) Holliger, P; Proc Natl Acad Sci USA 1993, V90, P6444 HCAPLUS
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d bib abs hitstr 7

L42 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2001 ACS
 AN 1999:405072 HCAPLUS
 DN 131:40593
 TI Human phosphatase homologs and cDNAs and methods for treatment of cancer and immune disorders
 IN Shah, Purvi; Hillman, Jennifer L.; Corley, Neil C.; Lal, Preeti
 PA Incyte Pharmaceuticals, Inc., USA
 SO PCT Int. Appl., 80 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9931225	A2	19990624	WO 1998-US25559	19981202
	WO 9931225	A3	19991014		
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	US 6242179	B1	20010605	US 1997-992035	19971217
	AU 9915414	A1	19990705	AU 1999-15414	19981202
	EP 1037967	A2	20000927	EP 1998-959660	19981202
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
PRAI	US 1997-992035	A2	19971217		
	WO 1998-US25559	W	19981202		
AB	The invention provides human phosphatases (HPA) and polynucleotides which identify and encode HPA. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists. The invention also provides methods for treating disorders assocd. with expression of HPA.				

=> d ind 7

L42 ANSWER 7 OF 8 HCAPLUS COPYRIGHT 2001 ACS
 IC ICM C12N009-00
 CC 3-3 (Biochemical Genetics)
 Section cross-reference(s): 1, 7, 13
 ST sequence human phosphatase homolog cDNA; cancer immune disorder treatment human phosphatase homolog antagonist
 IT Proteins, specific or class
 RL: **BPN (Biosynthetic preparation)**; BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (HPA-2, phosphatase sequence homolog; human phosphatase homologs and cDNAs and methods for treatment of cancer and immune disorders)
 IT Immunity
 (disorder; human phosphatase homologs and cDNAs and methods for treatment of cancer and immune disorders)
 IT Nucleic acid hybridization
 (for detection of phosphatase homolog nucleic acids; human phosphatase homologs and cDNAs and methods for treatment of cancer and immune disorders)
 IT cDNA sequences
 (for human phosphatase homologs HPA-1 and HPA-2)
 IT Antitumor agents
 (human phosphatase homologs and cDNAs and methods for treatment of cancer and immune disorders)
 IT Protein sequences
 (of human phosphatase homologs HPA-1 and HPA-2)
 IT Molecular cloning

- (of phosphatase homolog cDNAs; human phosphatase homologs and cDNAs and methods for treatment of cancer and immune disorders)
- IT Antibodies
 RL: ARG (Analytical reagent use); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
 (to phosphatase homologs; human phosphatase homologs and cDNAs and methods for treatment of cancer and immune disorders)
- IT 227298-58-0P 227298-60-4P
 RL: BPN (Biosynthetic preparation); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (amino acid sequence; human phosphatase homologs and cDNAs and methods for treatment of cancer and immune disorders)
- IT 9013-05-2DP, Phosphatase, sequence homologs
 RL: BPN (Biosynthetic preparation); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (human phosphatase homologs and cDNAs and methods for treatment of cancer and immune disorders)
- IT 227298-59-1P 227298-61-5P
 RL: BPN (Biosynthetic preparation); BUU (Biological use, unclassified); PRP (Properties); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (nucleotide sequence; human phosphatase homologs and cDNAs and methods for treatment of cancer and immune disorders)

=> d bib abs hitstr 8

L42 ANSWER 8 OF 8 HCAPLUS COPYRIGHT 2001 ACS

AN 1995:833473 HCAPLUS

DN 123:226044

TI Oxidation method for side chains of aromatic compounds and Ustilago species used in the process

IN Myaji, Shinya; Watanabe, Kikuo; Tanaka, Tooru; Suzuki, Takaya; Hotsuta, Yasushi

PA Petroleum Energy Center Found, Japan; Cosmo Oil Co Ltd

SO Jpn. Kokai Tokkyo Koho, 19 pp.


CODEN: JKXXAF

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 07184669	A2	19950725	JP 1993-332340	19931227
AB	Side chains of arom. compds. are oxidized with Ustilago sp. Ustilago sp. CRP-12 (FERM P-1420) was shake-cultured in a medium contg. salts, n-hexadecane, and 2,6-dimethylnaphthalene at 30.degree. for 7 days to manuf. 2,6-naphthalenedicarboxylic acid.				
IT	156-38-7P, p-Hydroxyphenylacetic acid RL: BMF (Bioindustrial manufacture); BPN (Biosynthetic preparation); BIOL (Biological study); PREP (Preparation) (manuf. of carboxylic acids by oxidn. of side chains of arom. compds. with Ustilago)				
RN	156-38-7 HCAPLUS				
CN	Benzeneacetic acid, 4-hydroxy- (9CI) (CA INDEX NAME)				





=> d bib abs fcdref

L49 ANSWER 1 OF 1 CASREACT COPYRIGHT 2001 ACS
 AN 131:350339 CASREACT
 TI Process for enzymic preparation of homogentisate
 IN Sailland, Alain; Derose, Richard
 PA Rhone Poulenc Agrochimie, Fr.
 SO Fr. Demande, 11 pp.
 CODEN: FRXXBL
 DT Patent
 LA French
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	FR 2772789	A1	19990625	FR 1997-16727	19971224
	FR 2772789	B1	20001124		
	WO 9934008	A1	19990708	WO 1998-FR2819	19981222
W:	AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KP, KR, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU	9918808	A1	19990719	AU 1999-18808	19981222
EP	1042496	A1	20001011	EP 1998-963586	19981222
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
PRAI	FR 1997-16727		19971224		
	WO 1998-FR2819		19981222		
AB	A procedure for producing homogentisate from 4-hydroxyphenylpyruvate is disclosed, characterized in that it consists of sequential enzymic reactions: conversion of 4-hydroxyphenylpyruvate to 4-hydroxyphenylacetate by an appropriate enzyme, followed by conversion of 4-hydroxyphenylacetate to homogentisate by a 2nd enzyme.				

RX(1) OF 3




REF: Fr. Demande, 2772789, 25 Jun 1999
 NOTE: biotransformation, enzymic, oxidase from Arthrobacter globiformis

OF 1 CASREACT COPYRIGHT 2001 ACS

=> d crdref

L49 ANSWER 1 OF 1 CASREACT COPYRIGHT 2001 ACS


RX(1) OF 3



REF: Fr. Demande, 2772789, 25 Jun 1999

NOTE: biotransformation, enzymic, oxidase from *Arthrobacter globiformis*

RX(2) OF 3



REF: Fr. Demande, 11 pp.; 1999

NOTE: biotransformation, enzymic, dioxygenase from *Pseudomonas acidovorans*

=> d bib abs fcrdref

L50 ANSWER 1 OF 1 CASREACT COPYRIGHT 2001 ACS

AN 129:230670 CASREACT

TI Oxidative decarbonylation of .beta.-arylpurvic acids using sodium perborate

AU Morrow, Nicholas; Ramsden, Christopher A.; Sargent, Bruce J.; Wallett, Christiaan D.

CS Dep. Chem., Keele Univ., Keele, ST5 5BG, UK

SO Tetrahedron (1998), 54(33), 9603-9612

CODEN: TETRAB; ISSN: 0040-4020


PB Elsevier Science Ltd.

DT Journal

LA English

AB Oxidn. of .beta.-arylpurvic acids and .beta.-heteroarylpurvic acids using sodium perborate tetrahydrate (SPB) in aq. soln. at ambient temp. gives the corresponding arylacetic acids in good yield (68-86%). The mild conditions are convenient for the prepn. of thermally unstable acids. In particular the method was applied to the prepn. of an unstable 5-nitro-1H-imidazole-2-acetic acid which could not be obtained using other reagents apparently due to enolization of the pyruvic acid precursor. Attempts to achieve decarbonylation using calcium hypochlorite or SPB in acidic soln. lead to the 2-chloromethyl derivs. The novel 5-nitro-1H-imidazole-2-acetic acid, which was required as a precursor of mols. of biol. interest, was fully characterized and converted to a known amide. Reaction of this acid with Vilsmeier's reagent gave an enamine deriv. and not the expected vinamidinium salt. This novel mode of reaction is attributable to intramol. hydrogen-bonding and favorable conjugation.

RX(5) OF 8



REF: Tetrahedron, 54(33), 9603-9612; 1998

OF 1 CASREACT COPYRIGHT 2001 ACS